BioNTech
BNTX
354 hedge funds and large institutions have $9.07B invested in BioNTech in 2021 Q4 according to their latest regulatory filings, with 80 funds opening new positions, 124 increasing their positions, 102 reducing their positions, and 59 closing their positions.
36% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 59
22% more repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 102
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
5% more funds holding
Funds holding: 336 → 354 (+18)
0.6% less ownership
Funds ownership: 15.39% → 14.79% (-0.6%)
9% less capital invested
Capital invested by funds: $10B → $9.07B (-$934M)
20% less call options, than puts
Call options by funds: $1.43B | Put options by funds: $1.77B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$166M |
| 2 |
PG
Pendal Group
Sydney,
Australia
|
+$137M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$102M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$95.4M |
| 5 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$83.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$396M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$278M |
| 3 |
Jennison Associates
New York
|
-$259M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$109M |
| 5 |
Millennium Management
New York
|
-$79.2M |
BNTX Hedge Fund Activity: Q4 2021 in Review
354 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q4 2021, worth a combined $9.07B — down 9.3% from $10B a quarter earlier.
Buyers outnumbered sellers: 80 funds opened new BNTX positions and 59 closed out — a net gain of 21 holders — while 124 added to existing stakes and 102 trimmed.
The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $166M. The largest seller was Fidelity Investments, cutting an estimated $396M.
- 354 institutional investors held BioNTech (BNTX) as of Q4 2021, up from 336 in Q3 2021.
- Funds reported $9.07B of BioNTech stock for Q4 2021, down 9.3% quarter-over-quarter.
- 80 funds opened new BioNTech positions in Q4 2021 and 59 closed out, a net change of +21 holders.
- The largest BioNTech buyer in Q4 2021 was Lord, Abbett & Co, an estimated $166M added.
- The largest BioNTech seller in Q4 2021 was Fidelity Investments, an estimated $396M sold.
Based on aggregated 13F filings for Q4 2021.